W1-1. Epidemiology and Prevalence of CRE/CPE

W1-2. Survey on the Current State of CRE Antibiotic Treatment and Guidelines for Antibiotic Use in CRE Infections in Korea

W1-3. The reality of treatment for CRE/CPE infection in clinical setting in Korea

Q & A Session

W2-1. Establishment of education system for experts training in antimicrobial stewardship program

W2-2. Quantitative evaluation of antimicrobial use and feedback to individual hospitals: suggestion for the use of KONAS result

W2-3. Evaluating Antimicrobial Utilization in Korean Long-Term Care Hospitals: A Call to Action for Antimicrobial Stewardship

Discussion

S1-1. Mechanisms and epidemiology of multiresistant non-fermenters

S1-2. Clinical implications and treatment of serious infections due to carbapenem resistant Pseudomonas aeruginosa

S1-3. Epidemiology and Treatment of Serious Infections Due to Carbapenem Resistant Acinetobacter baumannii.

S2-1. Inborn errors of cytosolic RNA sensors and severe COVID-19

S2-2. Vaccination in post-pandemic era and impact on long COVID

S2-3. Viral shedding kinetics in patients with SARS-CoV-2 infection

S3-1. The current situation of Antimicrobial Stewardship Program in Asia-Pacific countries

S3-2. Cutting-Edge Antimicrobial Stewardship: Strategies for Optimizing Therapy and Curbing Resistance in the Modern Era

S3-3. Integrating Emerging Technologies: Pioneering the Next Frontier in Antimicrobial Stewardship

K-1. Is antibiotic resistance stoppable?

K-2. The Modern World of Infectious Diseases: A Growing Challenge

K-3. Vaccines for AMR: an Overview

K-4. Update on Actions and Opportunities on Antimicrobial Resistance at NIH/NIAID

W3-1. Combating CRAB: New Therapeutics and Treatment Strategies

W3-2. Preventing CRAB: Effective Infection Control Strategies

P-1. Challenges in addressing the red plague of GNBs

P-2. Shaping Tomorrow's Antimicrobial Stewardship: The Crucial Contribution of Academic Institution

S4-1. Breaking New Ground in S. aureus Bacteremia: An Introduction to the SNAP Trial and Its Progress Thus Far

S4-2. Update in Staphylococcus aureus Bacteremia

S4-3. Periprosthetic Joint Infections caused by Staphylococcus aureus: current management approaches and antimicrobial strategies

S4-4. From Bedside to Bench and Back Again for MRSA Therapeutics

S5-1. Overview of Syndromic Testing: Rapid Multiplex PCR-guided Antimicrobial Stewardship and Clinical Benefits in Severe Infections

S5-2. Syndromic testing of respiratory infections

S5-3. Syndromic testing of gastrointestinal infections

S5-4. Syndromic testing of bone and joint infection

S6-1. Antibiotic Therapy for Special Populations

S6-2. Caution!: interpretation of plasma protein binding in PK/PD

S6-3. In vitro assessment of antimicrobial drug effect to guide personalized combination therapy.

S6-4. Microdialysis for measurement of tissue antibiotic concentration

P-3. Artificial intelligence: A new weapon to fight infectious diseases

P-4. Research Progress on Persistent MRSA Infection

S7-1. One Health Antibiotic Stewardship Collaborative

S7-2. The transmission of antimicrobial resistance at the human-animal-environment interface with genomics

S7-3. International trends in research on antibiotic resistance from the perspective of One Health

S7-4. Phylogenomic Analysis of Carbapenem-resistant Enterobacterales in a Veterinary Hospital

S8-1. Back to the basics: hand hygiene update

S8-2. Prevention of Non-Ventilator Hospital Acquired Pneumonia

S8-3. Automation in the practice of infection prevention and control

S9-1. Understanding of human microbiome from an ecological perspective

S9-2. Key determinants of success in fecal microbiota transplantation: from microbiome to clinic

S9-3. Strategies to Restore Colonization Resistance with Microbiome-based Therapeutics

W4-1. Collaboration cases of RWD research in Health Insurance Review and Assessment(HIRA) Research Institute

W4-2. Considerations for Clinical Studies Utilizing National Health Insurance Service Data

W4-3. Insights into Collaborative Medical Data Research Driven by Data Science

P-5. Current Status of Shorter Tuberculosis Treatment

P-6. Diagnostic Stewardship

S10-1. respiratory virus, RSV etc, maternal immunization

S10-2. Bacterial-Viral Co-infection

S10-3. Cytomegalovirus infection and drug resistance

S10-4. Unveiling the hidden burden of respiratory virus infections in adult

S11-1. How to mitigate multidrug resistant GNB spread through water control in healthcare settings

S11-2. Control Clostridioides difficile in healthcare: what to consider?

S11-3. How to reduce the risk of MDR pathogens in ICUs using environmental design: single rooms are better?

S12-1. Clinical utility of biomarkers in infectious diseases

S12-2. Application of NGS in clinical microbiology and infection control

S12-3. Enhancing clinical impact of new parasitic disease detection technologies

S12-4. Rapid detection of CPE: Enhancing patient treatment and infection control

S13-1. Candida auris: epidemiology and antifungal resistance

S13-2. Antifungal stewardship in critically ill patients

S13-3. The antifungal pipeline: advances in the treatment of invasive mycoses

S14-1. Rapid ART initiation: why, how, and what to start

S14-2. Moving the needle: The role and impact of HIV self-testing on early diagnosis of HIV in Asia-Pacific

S14-3. Pre-exposure prophylaxis: A pillar for ending the HIV epidemic

S15-1. Influenza vaccination strategies in older adults

S15-2. Understanding vaccine effectiveness in terms of T cell immunity

S15-3. Pneumococcal vaccination strategies in adult population